Valmark Advisers Inc. Invests $306,000 in CVS Health Corporation (NYSE:CVS)

Valmark Advisers Inc. bought a new position in CVS Health Corporation (NYSE:CVS - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 4,515 shares of the pharmacy operator's stock, valued at approximately $306,000.

Several other large investors have also made changes to their positions in CVS. Hopwood Financial Services Inc. bought a new stake in CVS Health during the 4th quarter worth about $29,000. McIlrath & Eck LLC grew its holdings in CVS Health by 32.6% during the 4th quarter. McIlrath & Eck LLC now owns 707 shares of the pharmacy operator's stock worth $32,000 after acquiring an additional 174 shares during the last quarter. Providence First Trust Co bought a new stake in CVS Health during the 4th quarter worth about $42,000. Park Square Financial Group LLC bought a new stake in CVS Health during the 4th quarter worth about $43,000. Finally, PARK CIRCLE Co grew its holdings in CVS Health by 42.9% during the 4th quarter. PARK CIRCLE Co now owns 1,000 shares of the pharmacy operator's stock worth $45,000 after acquiring an additional 300 shares during the last quarter. Institutional investors own 80.66% of the company's stock.

CVS Health Stock Down 1.7%

CVS Health stock opened at $66.44 on Thursday. The company has a debt-to-equity ratio of 0.77, a current ratio of 0.82 and a quick ratio of 0.63. The firm has a market capitalization of $84.05 billion, a price-to-earnings ratio of 15.86, a PEG ratio of 0.97 and a beta of 0.56. The company's 50 day simple moving average is $64.81 and its 200 day simple moving average is $60.62. CVS Health Corporation has a fifty-two week low of $43.56 and a fifty-two week high of $72.51.

CVS Health (NYSE:CVS - Get Free Report) last announced its earnings results on Thursday, May 1st. The pharmacy operator reported $2.25 EPS for the quarter, topping the consensus estimate of $1.62 by $0.63. The firm had revenue of $94.59 billion for the quarter, compared to the consensus estimate of $93.07 billion. CVS Health had a net margin of 1.39% and a return on equity of 10.59%. The business's quarterly revenue was up 7.0% on a year-over-year basis. During the same period last year, the company posted $1.31 EPS. As a group, sell-side analysts anticipate that CVS Health Corporation will post 5.89 EPS for the current year.

Insiders Place Their Bets

In related news, Director Guy P. Sansone bought 1,570 shares of the company's stock in a transaction on Thursday, June 5th. The shares were purchased at an average cost of $63.70 per share, for a total transaction of $100,009.00. Following the acquisition, the director now owns 12,007 shares of the company's stock, valued at approximately $764,845.90. This represents a 15.04% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 1.22% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the stock. Mizuho increased their price objective on shares of CVS Health from $70.00 to $76.00 and gave the stock an "outperform" rating in a report on Wednesday, April 9th. Robert W. Baird increased their price objective on shares of CVS Health from $51.00 to $71.00 and gave the company a "neutral" rating in a report on Tuesday, April 15th. Wall Street Zen raised shares of CVS Health from a "hold" rating to a "buy" rating in a research note on Friday, May 9th. Truist Financial raised their price objective on shares of CVS Health from $82.00 to $84.00 and gave the company a "buy" rating in a research note on Monday, May 12th. Finally, Royal Bank Of Canada raised their price objective on shares of CVS Health from $74.00 to $81.00 and gave the company an "outperform" rating in a research note on Monday, May 5th. Two equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $74.75.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.